Literature DB >> 6318653

Efficacy and safety of ceftriaxone in serious pediatric infections.

S C Aronoff, D Murdell, C A O'Brien, J D Klinger, M D Reed, J L Blumer.   

Abstract

Thirty-four patients aged 1 month to 19 years were treated with ceftriaxone for suspected bacterial infections. Bacterial pathogens were isolated from 25 children. The overall bacterial cure rate was 88%, with an overall clinical response rate of 96%. No side effects requiring cessation of therapy were observed. Ceftriaxone proved to be safe and effective in the treatment of serious infections in children.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6318653      PMCID： PMC185918          DOI： 10.1128/AAC.24.5.663

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents.

Authors:  I H Patel; R E Weinfeld; J Konikoff; M Parsonnet
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

2.  Multiple intravenous dose pharmacokinetics of ceftriaxone in man.

Authors:  I H Patel; K Miller; R Weinfeld; J Spicehandler
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

3.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

4.  Efficacy of ceftriaxone in serious bacterial infections.

Authors:  J S Epstein; S M Hasselquist; G L Simon
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

5.  Single-dose pharmacokinetics of ceftriaxone in infants and young children.

Authors:  U B Schaad; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

Review 6.  Reports on cephtriaxone (Rocephin). Introduction and review.

Authors:  M Fernex; L Havas
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

7.  In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.

Authors:  B T McNamara; R D Meyer; K A Pasiecznik
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

8.  Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.

Authors:  T C Eickhoff; J Ehret
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191
  8 in total
  3 in total

1.  Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics.

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

2.  Once-daily ceftriaxone therapy for serious bacterial infections in children.

Authors:  B L Congeni; T Chonmaitree; T A Rakusan; Q T Box
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

3.  Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.

Authors:  M D Reed; C A O'Brien; S C Aronoff; J D Klinger; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.